Bevacizumab - Biologic Drug Details

Summary for bevacizumab

Tradenames:	1
High Confidence Patents:	24
Applicants:	6
BLAs:	6
Suppliers: see list	7
Recent Clinical Trials:	See clinical trials for bevacizumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bevacizumab

Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	PHASE2
City of Hope Medical Center	PHASE3
M.D. Anderson Cancer Center	EARLY_PHASE1

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
GENENTECH, INC. v. SHANGHAI HENLIUS BIOTECH, INC.	2025-08-14
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC.	2023-11-17
Genentech, Inc. v. Biogen MA Inc.	2023-07-13

See all bevacizumab litigation

PTAB Litigation

Petitioner	Date
Pfizer Inc.	2018-01-05

See all bevacizumab litigation

Pharmacology for bevacizumab

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2033-10-12
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2035-07-31
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2028-07-08

2) High Certainty: US Patents for bevacizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2036-03-28	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2033-09-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2036-12-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for bevacizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2036-03-28	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2033-09-12	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2036-12-09	Patent claims search

International Patents for bevacizumab

Country	Patent Number	Estimated Expiration
European Patent Office	3558039
Denmark	2014678
Canada	3109693

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
23/2006	Austria		PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
SPC/GB06/025	United Kingdom		PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627
91271	Luxembourg		91271, EXPIRES: 20200125

Bevacizumab: Market Dynamics and Financial Trajectory

Last updated: April 27, 2026

Bevacizumab (AVASTIN, Roche/Genentech) is a mature oncology biologic with sustained global demand driven by broad solid-tumor coverage, entrenched provider use, and ongoing label expansion into earlier lines in multiple cancers. Revenue has historically shown steady growth through successive indications and geography expansion, then shifted into a mixed trajectory as biosimilar penetration increased in the US and other markets, as payer pressure intensified, and as new line-of-therapy standards evolved. The financial path is anchored by (1) top-line dependence on metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), and other major solid tumors, (2) aggressive lifecycle management via dosing and combination optimization, and (3) competition effects from biosimilars and originator pricing.

Where does bevacizumab generate demand, and how do oncology treatment patterns shape it?

Bevacizumab is used across multiple solid tumors as an angiogenesis inhibitor that is typically paired with cytotoxic chemotherapy and sometimes with other targeted agents. The commercial demand is therefore linked to two dynamics: (1) how frequently patients receive anti-VEGF therapy as standard-of-care in a given line, and (2) the survival and progression benefit that supports adoption by clinicians and payers.

Key commercial demand pools by indication (global, originator-led):

• Metastatic colorectal cancer (mCRC): sustained use in first-line and later lines in many jurisdictions as part of standard chemo backbones.
• Non-small cell lung cancer (NSCLC): backbone use in metastatic disease settings, including combinations with platinum-based chemotherapy and maintenance strategies in appropriate regimens.
• Renal cell carcinoma (RCC): adoption influenced by sequencing against other VEGF-pathway TKIs and immunotherapy combinations.
• Ovarian cancer and other gynecologic tumors: usage depends on guideline endorsement and availability of platinum sensitivity categories.
• Glioblastoma and other less uniform geographies/uptake areas: demand exists but is typically more variable across markets due to label scope, guideline positions, and reimbursement.

Treatment-pattern mechanics that drive volume and pricing:

• Line-of-therapy stability vs. churn: where anti-VEGF remains anchored in first-line or maintenance, volume stays sticky. Where standards shift toward immunotherapy-heavy paradigms or alternate VEGF targets, bevacizumab can lose share even if total anti-angiogenesis demand rises.
• Combination dependency: bevacizumab share tracks the prescribing habits of regimen choice (chemotherapy partner selection, duration, and maintenance).
• Payer authorization friction: high-cost infusion biologics face utilization management (step edits, prior authorization, preferred formulary status). Biosimilar availability tends to reduce authorization friction and increases switching.

What is the competitive landscape, and how does biosimilar entry change pricing power?

Bevacizumab is one of the most actively biosimilar-contested antibodies. Competition acts through both price compression and contract design. The commercial result is usually a step-down in net realized price after biosimilar launches and subsequent further declines driven by tendering and reference pricing.

How biosimilars typically shift the originator financial profile:

• Market share migration: hospitals and oncology centers often switch when biosimilars are designated preferred products.
• Net price compression: list-to-net dynamics tighten due to rebates, tender wins by biosimilar makers, and payer-led discounts.
• Reduced co-pay and reimbursement friction: patients and providers get faster access to lower-cost options, which accelerates switching.
• Geographic stagger effects: originator performance may look stronger in markets where biosimilars enter later or are less preferred.

Biosimilar pipeline reality that matters for the trajectory:

• Biosimilar approvals for bevacizumab have been established in multiple jurisdictions, with US entry catalyzing earlier price pressure than many other global markets.
• Competitive intensity is highest in settings where bevacizumab is used broadly across large populations (mCRC, NSCLC), because tendering drives high-volume conversion.

How has the financial trajectory evolved from launch-era growth to maturity?

Originator baseline: steady expansion then maturity

The originator’s long-run revenue trajectory follows a standard biologics pattern:

1. Indication expansion and guideline entrenchment increase eligible patient pools.
2. Geography scale-up expands reimbursement and administration capacity.
3. Lifecycle optimization (dose schedules, combination selection) sustains utilization.
4. Patent/biosimilar timelines then begin to flatten revenue growth and eventually drive declines.

Current-stage economics: volume resilience offset by net price erosion

As biosimilar competition strengthens, revenue typically splits into two forces:

• Volume resilience: continued overall adoption of anti-VEGF therapy sustains some demand even as branded share declines.
• Net price erosion: biosimilars reduce realized price, and contracting frameworks increasingly price by reference product.

This combination yields an earnings profile that can still generate large revenue totals but with reduced growth rate and higher sensitivity to payer mix.

What do the patent and exclusivity milestones imply for financial timing?

Bevacizumab’s competitive cycle is strongly tied to originator patent expiries and biosimilar market entry. In the US, the legal and regulatory framework shaped when biosimilar manufacturers could launch and when payers could confidently switch.

Core timeline logic:

• Exclusivity barriers fall: when relevant patents and exclusivity periods end, biosimilar makers can commercialize.
• Switching accelerates after tendering: hospitals adopt biosimilars via pharmacy and infusion center contracts.
• Revenue shifts from brand to biosimilar: originator revenue can decline even if overall patient demand remains stable.

The financial trajectory therefore has predictable inflection points: brand growth peaks pre-launch of competition, then the originator experiences margin and market-share pressure.

How do Roche/Genentech and the broader oncology portfolio dynamics affect bevacizumab performance?

Bevacizumab sits inside a broader Roche oncology portfolio that influences channel leverage and contracting strength:

• Roche has historically used multi-product oncology relationships (diagnostics, targeted therapies, immunotherapies) to sustain access and influence formulary decisions.
• When immunotherapy combinations change prescribing patterns, bevacizumab can experience share changes even without loss of label, depending on whether clinicians prefer anti-VEGF plus chemo or switch toward immunotherapy-dominant regimens.
• Budget impact is central in oncology. Anti-VEGF spend is often evaluated against competing regimens, and biosimilar availability typically changes the calculus in favor of lower-cost anti-VEGF options.

What are the key market dynamics that can still support growth or stabilize revenue?

Even in a maturing and competitive environment, bevacizumab can retain growth or stabilization factors:

1. Large eligible populations in major solid tumor indications

   • mCRC and NSCLC remain major engines where adoption can persist across multiple lines and geographies.

2. Guideline embedding and clinician inertia

   • Established regimens create switching friction, especially when infusion center protocols take time to update.

3. Combination regimen optimization

   • Ongoing real-world practice supports combination durability where clinical benefit is clear and well-accepted.

4. Geography mix

   • Biosimilar adoption intensity differs by country. Where biosimilar penetration is slower, originator performance can hold up longer.

What are the headwinds most likely to drive declines?

The most direct headwinds are structural:

1. Biosimilar-led price compression

   • Tenders and reference pricing drive net realized price down.

2. Formulary preference shifts

   • Hospitals often move to one or a limited set of preferred products. Once biosimilars are preferred, branded share erodes.

3. Therapy sequencing changes

   • As immunotherapy combinations evolve, clinicians may alter regimen choice, affecting anti-VEGF use frequency even if bevacizumab remains effective.

4. Payer budget pressure

   • High-cost infusion therapies face utilization management tightening, especially where biosimilars reduce therapeutic interchange barriers.

Financial trajectory indicators to monitor (so investors can map direction to drivers)

The trajectory can be assessed through a small set of observable leading indicators:

• Net price vs. list price gap for bevacizumab and competitive products (widening gap signals biosimilar-driven contracting and rebates).
• Share of preferred formulary status at large hospital systems (switching accelerates after preference changes).
• Biosimilar penetration rates by geography and line-of-therapy (first-line conversions often indicate more aggressive contracting than later-line).
• Roche oncology mix and payer contracting strategies (portfolio leverage can slow decline but rarely reverses market-share loss once biosimilars dominate).

Competitive and regulatory landscape: how it shapes the revenue curve

US biosimilar impact channel

• US launches of bevacizumab biosimilars typically bring rapid pricing pressure because contracts can be renegotiated quickly and formulary switches can be implemented at scale.

International channel complexity

• Outside the US, biosimilar uptake depends on reimbursement systems, tendering rules, and prescriber comfort. Net impact can lag the US, making the global trajectory uneven.

Bottom-line market outlook (directional)

Bevacizumab’s market is likely to remain large due to its entrenched oncology role, but financial performance is expected to be governed by biosimilar competition and payer contracting. The branded originator curve should show continued pressure on net realized price and market share in high-penetration markets, with partial stabilization where biosimilar uptake is slower or where clinical standards still anchor bevacizumab combinations.

Key Takeaways

• Bevacizumab demand is anchored in major solid tumors (notably mCRC and NSCLC), but its financial trajectory is dominated by net price erosion and biosimilar-led switching.
• The revenue curve follows a maturity pattern: post-indication expansion stability, then step-down dynamics tied to biosimilar entry and contracting.
• Market outcomes are more sensitive to formulary and tendering than to label changes alone; monitoring preferred formulary share and penetration is more predictive than tracking clinical trial headlines.
• Geographic mix can delay declines in regions with slower biosimilar adoption, but global financial trajectory trends align with competitive intensity.

FAQs

1. Will bevacizumab revenue collapse immediately after biosimilar entry?
   No. Originator revenue typically declines in phases as contracts are renegotiated, formulary preferences update, and switching takes hold across infusion sites.

2. Which indications matter most for the commercial ceiling?
   mCRC and metastatic NSCLC are core demand drivers due to large patient populations and durable regimen use.

3. Does Roche’s broader oncology portfolio change bevacizumab outcomes?
   It can slow share loss through contracting leverage and multi-product hospital relationships, but it does not eliminate price compression once biosimilars become preferred.

4. What drives net realized price most: volume loss or discounting?
   Discounting and contracting (rebates, tender discounts, reference pricing) usually drive the larger immediate net price impact.

5. How should investors interpret “revenue stability” in maturity?
   Stability often indicates successful lifecycle management and residual volume retention, but it can mask margin compression if net price is falling behind.

---

References (APA)

[1] European Medicines Agency. (n.d.). Avastin: EPAR product information. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. (n.d.). Avastin (bevacizumab) prescribing information. https://www.accessdata.fda.gov/
[3] FDA. (n.d.). Biosimilar product information for bevacizumab. https://www.fda.gov/biologicsblood-vaccines/biosimilars